Date | | | November 21, 2024 | |||||||||
Location | | | Zurich / Zoom | |||||||||
Name | | Kuno Sommer, Thomas Meier, Torsten Wöhr, | ||||||||||
Günther Loidl, Alain Schaffter | |||||||||||
Introduction
Mission Update
Market
Capacity & Innovation
Financing
Summary
Q&A
Kuno Sommer, Chairman
Thomas Meier, CEO & COO
Torsten Wöhr, CCO
Günther Loidl, CTO
Alain Schaffter, CFO
Thomas Meier, CEO & COO
All
2 Bachem CMD 2024
Majority shareholder, | Discipline, expertise & | Serving the enormous | Complexity of a | Many "firsts" - | ||
long-term committed | perseverance have | growth in demand for | larger, more diverse | Changing market | ||
to sustainable growth | built a global leader | TIDES as active | organization | landscape, new | ||
for TIDES | ingredients | customer | ||||
requirements drive | ||||||
industry change | ||||||
3 Bachem CMD 2024
Contract development and | Broad capabilities | |
manufacturing organization | in PepTIDES and | |
(CDMO) | OligonucleoTIDES active | |
pharmaceutical ingredients | ||
(API) manufacturing | ||
Long-term partnerships | Focused on chemical | Annual sales of CHF 577.3 |
with pharmaceutical and | synthesis, committed | million in 2023 and over |
biotech companies | to innovation | 2'000 colleagues worldwide |
4 Bachem CMD 2024
Tides | Biology | ||
Peptides | • | Molecules of up to approx. 100 amino | |
acids | |||
• | Occur naturally in the body, e.g. as a | ||
hormone |
Applications (examples)
- Cancer
- Metabolic, cardiovascular diseases, diabetes & obesity
- Neuronal disorders
- Cosmetics
- In-vitrodiagnostics (IVD)
Oligonucleotides | • | Fragments of DNA or RNA | • | Mostly applied as "orphan drugs" |
• | Suppress the creation | • | Expanding to chronic diseases | |
of specific proteins |
TIDES can be modified | Their complexity makes | Requiring specific |
chemically to serve as | TIDES a domain for | knowledge, equipment |
active drug ingredient. | specialists. | & infrastructure. |
5 Bachem CMD 2024
600 | 577.3 | 2500 | |||||||
531.7 | |||||||||
500 | 503.2 | ||||||||
2000 | |||||||||
2006 | 2009 (H1) | ||||||||
400 | 402.0 | 1776 | |||||||
1639 | 1500 | ||||||||
313.7 | 1475 | ||||||||
300 | 261.6 | 282.5 | |||||||
236.5 | 1209 | ||||||||
1097 | 1000 | ||||||||
1057 | |||||||||
979 | |||||||||
200 | |||||||||
100 | 500 | ||||||||
0 | 0 | ||||||||
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
H1 sales | H2 sales | FY sales | Employees (FTE) | |||
6 Bachem CMD 2024
TIDES are the next in a history of pharma game changers
…new medicines that revolutionize the way
we treat large population diseases:
The 1990's
HIV | Kinase | Hep C | Anti-PD-1 |
Drugs | Inhibitors | Drugs | in Cancer |
7 Bachem CMD 2024
mRNA Vaccine
TODAY
Incretins,
Amylin, PYY
Peptides
Market
dynamic
Incretins,
Amylin, PYY
Peptides
Bachem
Strategic
imperatives
8 Bachem CMD 2024
- Urgent need for TIDES capacity
- Potential new market entrants
Short-term
• Execute large-scale
Capture | opportunity | |
growth | ||
• | Capacity expansion | |
potential | ||
• | Operational efficiency |
- Process innovation required to increase yields
- Regulation & imperative toward green chemistry
- Near-shoringeffect
Long-term
• Lead in TIDES expertise | ||
Ensure | • | Process R&D |
long-term | ||
• | Green chemistry | |
competiti | ||
veness | innovations | |
• | Strong pipeline |
Capture growth potential
Ensure long- term competitiveness
9 Bachem CMD 2024
CMO
Contract Manufacturing Organization
CDMO
Contract Development and Manufacturing Organization
«Trailblazing» CDMO
Going beyond today's
technology standard
- Efficient high-quality manufacturing for approved drugs
- Contributes to supply of approved medicines for patients worldwide
- New technologies that address manufacturing challenges
- Open new ways in which TIDES can be made as ingredients for medicines
- New technologies that address manufacturing challenges
- Open new ways in which TIDES can be made as ingredients for medicines
Transformation to leverage all capabilities
- Network strategy: Evolve from a headquarter-satellite approach to an even more integrated network.
- Strengthen management: Develop & expand talent base to strengthen CMO/large-scale skillset.
10 Bachem CMD 2024
Transformation to leverage all capabilities
One-pot LPOS
- Allow for scalability: Reduce complexity in structures and processes. Simplicity avoids errors and mistakes.
- CAPEX-delivery: Structured and scalable approach to large capital investments.